62000-10-6

Upstream product

• 601-89-8 2-nitroresorcinol 
• 100-39-0 benzyl bromide 

Downstream Products

• 213685-59-7 2-nitroresorcinol monobenzyl ether 
• 1372616-32-4 3-(4-(4-(2-(1H-imidazol-1-yl)ethyl)piperazin-1-yl)butoxy)-2-aminophenol 
• 1372616-35-7 1-(4-(4-(2-amino-3-hydroxyphenoxy)butyl)piperazin-1-yl)-2-(1H-imidazol-1-yl)ethanone 
• 1386274-53-8 C₂HF₃O₂*C₂₁H₂₇N₃O₄ 
• 1372616-27-7 2-(3-(benzyloxy)-2-nitrophenoxy)-N,N-diethylethanamine 
• 1372616-28-8 2-amino-3-(2-(diethylamino)ethoxy)phenol 
• 1372616-29-9 1-(benzyloxy)-3-(4-bromobutoxy)-2-nitrobenzene 
• 1372616-30-2 1-(2-(1H-imidazol-1-yl ) ethyl)-4-(4-(3-(benzyloxy)-2-nitrophenoxy)butyl)piperazine 
• 1372616-33-5 tert-butyl 4-(4-(3-(benzyloxy)-2-nitrophenoxy)butyl)piperazine-1-carboxylate 
• 1372616-31-3 1-(4-(4-(3-(benzyloxy)-2-nitrophenoxy)butyl)piperazin-1-yl)-2-(1H-imidazol-1-yl)ethanone 
• 61999-92-6 2,6-di(benzyloxy)aniline 
• 1442655-90-4 N-(4-(2-amino-3-hydroxyphenoxy)butyl)-5-(dimethylamino)-N-methylnaphthalene-1-sulfonamide 
• 1442655-86-8 N-(2-(2-amino-3-hydroxyphenoxy)ethyl)-5-(dimethylamino)-N-methylnaphthalene-1-sulfonamide 
• 1442655-89-1 N-(4-(3-benzyloxy-2-nitrophenoxy)butyl)-5-(dimethylamino)-N-methylnaphthalene-1-sulfonamide 

Relevant academic research and scientific papers

THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES

A therapeutic agent for treating at least one disease selected from the group consisting of inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases, comprising: at least one selected from the group consisting of a compound represented by the following general formula (1) and pharmacologically acceptable salts thereof as an active ingredient. [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: -CH2-, - CH2-CH2-, -CH2-CH2-CH2-, or -CH2-O-CH2-; and Z represents a hydrogen atom or a hydroxyl group.]

CRYSTAL OF BENZOXAZOLE DERIVATIVE

Provided are crystals of 1-((2-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-7-(thiazol-2-yl)benzo[d]oxazol-4-yl)oxy)-1,1-difluoro-2-methylpropan-2-ol represented by formula (1),

NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF

A compound represented by the general formula (1) below or a pharmacologically acceptable salt thereof: [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, or —CH2—O—CH2—; and Z represents a hydrogen atom or a hydroxyl group.]

ANTIMICROBIAL COMPOUNDS

Provided herein is technology relating to antimicrobial compounds and particularly, but not exclusively, to analogs of rifalazil having increased inhibition of RNA polymerase and decreased induction of human cy-tochrome P450. The compounds have an increased affinity for a bacterial RNA polymerase (e.g., a MTB RNA polymerase) and a decreased affinity for a human pregnane X receptor. Thus, in some embodiments, the steric clash of A or R with residues in the binding pocket of the human pregnane X receptor reduces an affinity of the compound for the human pregnane X receptor. Consequently, in some embodiments the steric clash thus reduces the induction (e.g., an activity) of a cytochrome P450 and/or other related proteins.

Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases

By utilization of three-dimensional structure information of rifamycins bound to RNA polymerase (RNAP) and the human pregnane X receptor (hPXR), representative examples (2b-d) of a novel subclass of benzoxazinorifamycins have been synthesized. Relative to rifalazil (2a), these analogues generally display superior affinity toward wild-type and Rif-resistant mutants of the Mycobacterium tuberculosis RNAP but lowered antitubercular activity in cell culture under both aerobic and anaerobic conditions. Lowered affinity toward hPXR for some of the analogues is also observed, suggesting a potential for reduced Cyp450 induction activity. Mouse and human microsomal studies of analogue 2b show it to have excellent metabolic stability. Mouse pharmacokinetics in plasma and lung show accumulation of 2b but with a half-life suggesting nonoptimal pharmacokinetics. These studies demonstrate proof of principle for this subclass of rifamycins and support further expansion of structure-activity relationships (SARs) toward uncovering analogues with development potential.

Derivatives of 2-substituted-hydroxyanilino-hexahydro-2H-benzo[α]quinolizines

2-Substituted-hydroxyanilino-hexahydro-2H-benzo[α]quinolizines of the structural formula, SPC1 In which R1 is a hydrogen atom or an alkanoyl group of 2 to 4 carbon atoms and each of substituents R2, R3, R4, R5, and R6 is a hydrogen atom, a hydroxyl, or a methyl group, such that at least one of the latter substituents is a hydroxyl group, exhibit coronary vasodilating activity.